Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P10253: Variant p.Leu355Pro

Lysosomal alpha-glucosidase
Gene: GAA
Feedback?
Variant information Variant position: help 355 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 355 (L355P, p.Leu355Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GSD2; infantile form; severe; loss of activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 355 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 952 The length of the canonical sequence.
Location on the sequence: help GILDVYIFLGPEPKSVVQQY L DVVGYPFMPPYWGLGFHLCR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCR

Mouse                         GILDVYVFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCR

Rat                           GILDVYVFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCR

Bovine                        GILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCR
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 70 – 952 Lysosomal alpha-glucosidase
Chain 123 – 952 76 kDa lysosomal alpha-glucosidase
Chain 204 – 952 70 kDa lysosomal alpha-glucosidase
Helix 347 – 358



Literature citations
Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.
Hermans M.M.P.; van Leenen D.; Kroos M.A.; Beesley C.E.; Van der Ploeg A.T.; Sakuraba H.; Wevers R.; Kleijer W.J.; Michelakakis H.; Kirk E.P.; Fletcher J.; Bosshard N.; Basel-Vanagaite L.; Besley G.; Reuser A.J.J.;
Hum. Mutat. 23:47-56(2004)
Cited for: VARIANTS GSD2 GLY-103; ARG-219; ARG-285; CYS-292; ARG-293; PRO-308; ARG-312; PRO-355; ARG-374; PRO-405; PHE-455; ASP-459 DEL; ARG-478; ARG-481; THR-519; LEU-545; ARG-549; PRO-552; SER-575; LYS-579; CYS-600; ASP-607 AND ASP-880; CHARACTERIZATION OF VARIANTS; FUNCTION; Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease.
Montalvo A.L.E.; Cariati R.; Deganuto M.; Guerci V.; Garcia R.; Ciana G.; Bembi B.; Pittis M.G.;
Mol. Genet. Metab. 81:203-208(2004)
Cited for: VARIANTS GSD2 PRO-355 AND CYS-702; CHARACTERIZATION OF VARIANTS GSD2 PRO-355 AND CYS-702; Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.
Montalvo A.L.; Bembi B.; Donnarumma M.; Filocamo M.; Parenti G.; Rossi M.; Merlini L.; Buratti E.; De Filippi P.; Dardis A.; Stroppiano M.; Ciana G.; Pittis M.G.;
Hum. Mutat. 27:999-1006(2006)
Cited for: VARIANTS GSD2 ARG-309; PRO-355; LEU-361; PRO-445; ASN-489; ARG-549; GLN-612; ARG-643; TRP-672 AND CYS-746; Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
Muller-Felber W.; Horvath R.; Gempel K.; Podskarbi T.; Shin Y.; Pongratz D.; Walter M.C.; Baethmann M.; Schlotter-Weigel B.; Lochmuller H.; Schoser B.;
Neuromuscul. Disord. 17:698-706(2007)
Cited for: VARIANTS GSD2 PRO-355; ALA-522 AND VAL-610; VARIANT ARG-359; Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease.
Pittis M.G.; Donnarumma M.; Montalvo A.L.E.; Dominissini S.; Kroos M.; Rosano C.; Stroppiano M.; Bianco M.G.; Donati M.A.; Parenti G.; D'Amico A.; Ciana G.; Di Rocco M.; Reuser A.; Bembi B.; Filocamo M.;
Hum. Mutat. 29:E27-E36(2008)
Cited for: VARIANTS GSD2 GLY-103; CYS-191; ARG-219; TRP-224; LYS-262; ARG-293; PRO-355; LEU-375; ARG-401; ASN-489; ALA-522; PRO-552; TYR-599; TRP-638; ARG-643 AND ASN-645; CHARACTERIZATION OF VARIANTS GSD2 CYS-191; LEU-375; ARG-401; ALA-522 AND TYR-599; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.